Genomics and Population Health Action Collaborative
The Cascade Screening Working Group aimed to develop tools and best practices for the identification and genetic testing of at-risk relatives of those individuals diagnosed with familial hypercholesterolemia (FH), hereditary breast and ovarian cancer, and/or Lynch syndrome.
|Heather Hampel, M.S., L.G.C.
Licensed Genetic Counselor, Clinical Cancer Genetics Program
Professor, Division of Human Genetics
Department of Internal Medicine
The Ohio State University
Founder and CEO
The FH Foundation
Select participants from the group performed a scoping review of the literature on the delivery of cascade screening for hereditary conditions. Additional projects are ongoing including an exploration into HIPAA policy as it pertains to the direct contact of at-risk relatives.
The Genomics and Population Health Action Collaborative, is an ad hoc activity under the auspices of the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine (the National Academies). The products of the action collaborative do not necessarily represent the views of any one organization, the Roundtable, or the National Academies and have not been subjected to the review procedures of, nor are they a report or product of, the National Academies.
For more information about the Genomics and Population Health Action Collaborative, please click here.